Introduction.Candidaspp. are commensal fungal pathogens of humans, but when there is an imbalance in the microbiota, or weak host immunity, these yeasts can become pathogenic, generating high medical costs.Gap Statement.With the increase in resistance to conventional antifungals, the development of new therapeutic strategies is necessary.This study evaluated thein vitroantifungal activity of chlorogenic acid against fluconazole-resistant strains ofCandidaspp.Mechanism of action through flow cytometry andin silicoanalyses, as well as molecular docking assays with ALS3 and SAP5, important proteins in the pathogenesis ofCandida albicansassociated with the adhesion process and biofilm formation.Results.The chlorogenic acid showedin vitroantifungal activity against the strains tested, causing reduced cell viability, increased potential for mitochondrial depolarization and production of reactive oxygen species, DNA fragmentation and phosphatidylserine externalization, indicating an apoptotic process. Concerning the analysis through docking, the complexes formed between chlorogenic acid and the targetsThymidylate Kinase, CYP51, 1Yeast Cytochrome BC1 ComplexeExo-B-(1,3)-glucanasedemonstrated more favourable binding energy. In addition, chlorogenic acid presented significant interactions with the ALS3 active site residues ofC. albicans,important in the adhesion process and resistance to fluconazole. Regarding molecular docking with SAP5, no significant interactions were found between chlorogenic acid and the active site of the enzyme.Conclusion.We concluded that chlorogenic acid has potential use as an adjuvant in antifungal therapies, due to its anti-Candidaactivity and ability to interact with important drug targets.